SG11201601408PA - Stem cell modulation ii - Google Patents
Stem cell modulation iiInfo
- Publication number
- SG11201601408PA SG11201601408PA SG11201601408PA SG11201601408PA SG11201601408PA SG 11201601408P A SG11201601408P A SG 11201601408PA SG 11201601408P A SG11201601408P A SG 11201601408PA SG 11201601408P A SG11201601408P A SG 11201601408PA SG 11201601408P A SG11201601408P A SG 11201601408PA
- Authority
- SG
- Singapore
- Prior art keywords
- stem cell
- cell modulation
- modulation
- stem
- cell
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903589A AU2013903589A0 (en) | 2013-09-18 | Stem Cell Modulation II | |
| PCT/AU2014/050237 WO2015039187A1 (en) | 2013-09-18 | 2014-09-18 | Stem cell modulation ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601408PA true SG11201601408PA (en) | 2016-04-28 |
Family
ID=52688010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601408PA SG11201601408PA (en) | 2013-09-18 | 2014-09-18 | Stem cell modulation ii |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10124001B2 (en) |
| EP (1) | EP3046560B1 (en) |
| JP (2) | JP6998657B2 (en) |
| CN (1) | CN105764513A (en) |
| AU (1) | AU2014324092B2 (en) |
| CA (1) | CA2923765C (en) |
| ES (1) | ES2851724T3 (en) |
| SG (1) | SG11201601408PA (en) |
| WO (1) | WO2015039187A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10485772B2 (en) | 2014-08-25 | 2019-11-26 | EpiAxis Therapeutics Pty Ltd. | Compositions for modulating cancer stem cells and uses therefor |
| CA2984413A1 (en) * | 2015-04-30 | 2016-11-03 | Institute Of Immunology Co., Ltd. | Transgenic non-human animal expressing human specific molecule and human fc.gamma. receptor family |
| SG11201806122YA (en) | 2016-02-01 | 2018-08-30 | Univ Canberra | Proteinaceous compounds and uses therefor |
| WO2018209312A1 (en) * | 2017-05-12 | 2018-11-15 | Tew Gregory N | Ex vivo method of generating super regulatory t cells for the prevention of autoimmune disease |
| CN111587120A (en) * | 2017-11-08 | 2020-08-25 | 艾比克斯治疗私人有限公司 | Immunogenic compositions and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| CA2084987C (en) | 1990-06-11 | 2007-02-13 | Larry Gold | Nucleic acid ligands |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5151360A (en) * | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
| ATE237694T1 (en) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| ATE304604T1 (en) | 1993-06-24 | 2005-09-15 | Frank L Graham | ADENOVIRUS VECTORS FOR GENE THERAPY |
| ATE437232T1 (en) | 1993-10-25 | 2009-08-15 | Canji Inc | RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE |
| US5783405A (en) | 1994-02-01 | 1998-07-21 | Terrapin Technologies, Inc. | Rapid screening method for effectors of signal transduction |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CN1125817C (en) | 1996-02-13 | 2003-10-29 | 曾尼卡有限公司 | Quinazoline derivatives as VEGF inhibitors |
| CN1116286C (en) | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| AU3751299A (en) | 1998-04-20 | 1999-11-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| TW440494B (en) * | 1999-05-13 | 2001-06-16 | Sumitomo Spec Metals | Machining method of rare earth alloy and manufacture of rare earth magnet using it |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| JP5500750B2 (en) | 2000-03-30 | 2014-05-21 | ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ | RNA sequence specific mediator of RNA interference |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| AU6623201A (en) | 2000-07-07 | 2002-02-05 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| JP2004502766A (en) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | Colhinol derivatives as vascular damaging agents |
| AU2001286959B2 (en) | 2000-09-01 | 2007-09-06 | Ribozyme Pharmaceuticals, Incorporated | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
| US20020150936A1 (en) | 2000-09-01 | 2002-10-17 | Leonid Beigelman | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
| DE60130583T3 (en) | 2000-12-01 | 2018-03-22 | Europäisches Laboratorium für Molekularbiologie | SMALL RNA MOLECULES TRANSFERRING RNA INTERFERENCE |
| WO2002090595A1 (en) * | 2001-05-03 | 2002-11-14 | President And Fellows Of Harvard College | Methods for modulating an immune response by modulating krc activity |
| US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20050239731A1 (en) | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
| CA2482598C (en) | 2002-04-22 | 2012-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase c |
| EP1515964A1 (en) * | 2002-06-14 | 2005-03-23 | ALTANA Pharma AG | Substituted diaminopyrimidines |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| WO2004067516A1 (en) | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| WO2005039549A1 (en) | 2003-10-27 | 2005-05-06 | Novartis Ag | Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation |
| KR20070004571A (en) | 2003-12-11 | 2007-01-09 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | Homozyme-specific antagonists of protein kinase C |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ATE432260T1 (en) | 2005-03-28 | 2009-06-15 | Boehringer Ingelheim Int | PYRIDINE DERIVATIVES AS PKC-THETA INHIBITORS |
| US20080318929A1 (en) | 2005-12-21 | 2008-12-25 | Barbosa Antonio J M | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta |
| DE102006029447A1 (en) | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituted imidazo [1,2b] pyridazines, their preparation and use as pharmaceuticals |
| CA2658263A1 (en) * | 2006-07-18 | 2008-01-24 | University Of Rochester | Thiadiazolidinone derivatives |
| WO2009062059A2 (en) | 2007-11-08 | 2009-05-14 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| US8569337B2 (en) * | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| CN102131809A (en) | 2008-07-23 | 2011-07-20 | 沃泰克斯药物股份有限公司 | Tri-cyclic pyrazolopyridine kinase inhibitors |
| MX2011001319A (en) | 2008-08-06 | 2011-04-05 | Vertex Pharma | Aminopyridine kinase inhibitors. |
| US8436025B2 (en) | 2008-09-19 | 2013-05-07 | CompleGen Partners, Inc. | Compounds and methods for PKC theta inhibition |
| WO2010083207A2 (en) | 2009-01-15 | 2010-07-22 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| EP3825833B1 (en) | 2009-06-10 | 2022-08-03 | Hexagon Technology Center GmbH | Ontological filtering using spatial boundary of 3d objects |
| CA2787315A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| EP2528916A1 (en) | 2010-01-27 | 2012-12-05 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| CA2787079A1 (en) * | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
| UY34072A (en) * | 2011-05-17 | 2013-01-03 | Novartis Ag | INDOL SUBSTITUTED DERIVATIVES |
-
2014
- 2014-09-18 EP EP14845501.7A patent/EP3046560B1/en active Active
- 2014-09-18 US US15/023,358 patent/US10124001B2/en active Active
- 2014-09-18 CN CN201480051365.5A patent/CN105764513A/en active Pending
- 2014-09-18 WO PCT/AU2014/050237 patent/WO2015039187A1/en not_active Ceased
- 2014-09-18 ES ES14845501T patent/ES2851724T3/en active Active
- 2014-09-18 SG SG11201601408PA patent/SG11201601408PA/en unknown
- 2014-09-18 AU AU2014324092A patent/AU2014324092B2/en active Active
- 2014-09-18 CA CA2923765A patent/CA2923765C/en active Active
- 2014-09-18 JP JP2016543268A patent/JP6998657B2/en active Active
-
2018
- 2018-11-12 US US16/186,786 patent/US10736892B2/en active Active
-
2020
- 2020-08-27 JP JP2020143662A patent/JP2021006530A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016537400A (en) | 2016-12-01 |
| US10736892B2 (en) | 2020-08-11 |
| JP6998657B2 (en) | 2022-02-04 |
| AU2014324092B2 (en) | 2020-02-06 |
| CN105764513A (en) | 2016-07-13 |
| JP2021006530A (en) | 2021-01-21 |
| US20190192509A1 (en) | 2019-06-27 |
| EP3046560A1 (en) | 2016-07-27 |
| US20160354367A1 (en) | 2016-12-08 |
| CA2923765C (en) | 2021-06-29 |
| EP3046560B1 (en) | 2021-01-06 |
| CA2923765A1 (en) | 2015-03-26 |
| US10124001B2 (en) | 2018-11-13 |
| AU2014324092A1 (en) | 2016-03-10 |
| WO2015039187A1 (en) | 2015-03-26 |
| EP3046560A4 (en) | 2017-06-14 |
| ES2851724T3 (en) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245572B (en) | Cell | |
| AU356417S (en) | Battery | |
| HUE042190T2 (en) | Ohmically modulated battery | |
| GB201302468D0 (en) | Stem cell product | |
| GB201310031D0 (en) | Cell | |
| SI2868953T1 (en) | Valve | |
| GB201312332D0 (en) | Cell locations | |
| SG11201601408PA (en) | Stem cell modulation ii | |
| PL3052840T3 (en) | Valve | |
| EP3038195A4 (en) | Lithium cell | |
| GB2516094B (en) | Valve | |
| GB201303101D0 (en) | Media for stem cells | |
| GB2532681B (en) | Envelope modulator | |
| HU4514U (en) | Valve | |
| GB201304537D0 (en) | Valve | |
| GB201321601D0 (en) | Modulator | |
| GB201312803D0 (en) | Cell component | |
| GB2537466B (en) | Valve | |
| AU2013903589A0 (en) | Stem Cell Modulation II | |
| AU2013902309A0 (en) | Stem cell modulation | |
| GB2516044B (en) | Valve | |
| GB2515548B (en) | Valve | |
| GB201320573D0 (en) | T Cell | |
| GB201317589D0 (en) | Cell | |
| GB201303132D0 (en) | Cell Line |